Impact of antifibrotic drugs in lung transplantation

Introduction: It has been postulated that antifibrotics could increase the incidence of post-transplantation complications in patients with idiopathic pulmonary fibrosis (IPF). The aim of our study is to analyze the incidence of complications and survival in patients with IPF treated and not treated with antifibrotic drugs. Material and methods: We performed a retrospective study of trasplanted patients with IPF between 2013 and 2018 at the Puerta de Hierro Hospital. Demographic, functional variables, antifibrotic treatment, immediate complications and 3 years follow-up survival were collected. Results: 40 patients were included. There were no significant differences between baseline characteristics of the groups. There were no significant differences in the ratio of complications at 28 days (Table 1). There were significant differences in 3-year survival favouring the antifibrotic group (Figure 1). Conclusions: The use of antifibrotic drugs in patients with IPF prior to lung transplantation does not influence immediate morbility and could be associated with increased survival. Table 1. Complications: